



HAL
open science

The contribution of arterial calcification to peripheral arterial disease in pseudoxanthoma elasticum

Georges Lefthériotis, Gilles Kauffenstein, Jean-François Hamel, Pierre Abraham, Olivier Le Saux, Serge Willoteaux, Daniel Henrion, Ludovic Martin

► **To cite this version:**

Georges Lefthériotis, Gilles Kauffenstein, Jean-François Hamel, Pierre Abraham, Olivier Le Saux, et al.. The contribution of arterial calcification to peripheral arterial disease in pseudoxanthoma elasticum. PLoS ONE, 2014, 9 (5), pp.96003. 10.1371/journal.pone.0096003 . hal-03404134

HAL Id: hal-03404134

<https://univ-angers.hal.science/hal-03404134>

Submitted on 26 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



The Contribution of Arterial Calcification to Peripheral Arterial Disease in Pseudoxanthoma Elasticum

Georges Leftheriotis^{1,2*}, Gilles Kauffenstein², Jean François Hamel⁵, Pierre Abraham^{1,2}, Olivier Le Saux³, Serge Willoteaux^{1,4}, Daniel Henrion², Ludovic Martin^{1,2}

1 PXE Health and Research Center, University Hospital of Angers, Angers, France, **2** UMR CNRS 6214 - Inserm 1083, School of Medicine, l'UNAM University, Angers, France, **3** Department Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America, **4** UPRES 3860, School of Medicine, l'UNAM University, Angers, France, **5** Clinical Research Center, University Hospital of Angers, Angers, France

Abstract

Background and aims: The contribution of arterial calcification (AC) in peripheral arterial disease (PAD) and arterial wall compressibility is a matter of debate. Pseudoxanthoma elasticum (PXE), an inherited metabolic disease due to *ABCC6* gene mutations, combines elastic fiber fragmentation and calcification in various soft tissues including the arterial wall. Since AC is associated with PAD, a frequent complication of PXE, we sought to determine the role of AC in PAD and arterial wall compressibility in this group of patients.

Methods and Results: Arterial compressibility and patency were determined by ankle-brachial pressure index (ABI) in a cohort of 71 PXE patients (mean age 48 ± 5 SD 14 yrs, 45 women) and compared to 30 controls without PAD. Lower limb arterial calcification (LLAC) was determined by non-contrast enhanced helical CT-scan. A calcification score (Ca-score) was computed for the femoral, popliteal and sub-popliteal artery segments of both legs. Forty patients with PXE had an $ABI < 0.90$ and none had an $ABI > 1.40$. LLAC increased with age, significantly more in PXE subjects than controls. A negative association was found between LLAC and ABI ($r = -0.363$, $p = 0.002$). The LLAC was independently associated with PXE and age, and ABI was not linked to cardiovascular risk factors.

Conclusions: The presence of AC was associated with PAD and PXE without affecting arterial compressibility. PAD in PXE patients is probably due to proximal obstructive lesions developing independently from cardiovascular risk factors.

Citation: Leftheriotis G, Kauffenstein G, Hamel JF, Abraham P, Le Saux O, et al. (2014) The Contribution of Arterial Calcification to Peripheral Arterial Disease in Pseudoxanthoma Elasticum. PLoS ONE 9(5): e96003. doi:10.1371/journal.pone.0096003

Editor: Philipp Eller, Medical University of Graz, Austria

Received: February 13, 2014; **Accepted:** April 1, 2014; **Published:** May 6, 2014

Copyright: © 2014 Leftheriotis et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: French Society of Vascular Medicine (SFMV), University Hospital of Angers (contract # 2010-A00142-37 and #2011-A00942-39) and the PXE-France Patients' Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: geleftheriotis@chu-angers.fr

Introduction

Arterial calcification (AC) is an independent risk factor for cardiovascular disease [1], including peripheral arterial disease (PAD) [2]. The role of arterial calcification in PAD is unclear but is related to the site and location of calcification within the arterial layers. Intimal calcification is frequently associated with atherosclerosis, whereas calcification of the medial layers is frequently associated with aging or acquired metabolic diseases (such as diabetes and chronic renal insufficiency) and usually associated with arterial stiffening [3]. Arterial calcification has also been reported in young patients with a range of inherited monogenic diseases as a result of impaired regulation of soft tissue calcification [4]. Pseudoxanthoma elasticum (PXE; OMIM 264800, prevalence 1/25000 to 1/50000) is an autosomal recessive multisystem disease resulting from mutations in *ABCC6* that encodes an ATP-binding cassette transporter mainly expressed in the liver and kidneys [5,6]. This disease is mainly characterized by progressive calcification of the elastic fibers in the skin, retinal Bruch's membrane and the medial layers of large and medium sized peripheral arteries. PXE patients therefore seem to develop

cardiovascular events and complications, including PAD, at a younger age than the normal population, although without obvious cardiovascular risk factors [7–11]. Using the ankle-brachial index, an index screening for PAD, our group recently confirmed a high prevalence of PAD in a large cohort of PXE [12–13]. Unexpectedly, our findings revealed preserved arterial wall compressibility despite the presence of medial calcification in PXE, suggesting that AC might not play a direct role in the development of PAD in PXE. Since calcifications throughout the coronary and peripheral artery vasculature can be determined quantitatively and characterized using non-invasive computed tomography [14], we designed the study presented here to determine the association between AC in the lower limbs (LLAC) and PAD in PXE. The elective site of LLAC was also examined, as well as the impact of cardiovascular risk factors in the calcification process and PAD.

Materials And Methods

Study population

Seventy-one consecutive PXE patients were enrolled in this study at the PXE Consultation Center of the University Hospital

of Angers, France. The diagnosis of PXE was based on a combination of established criteria for indisputable PXE, including clinically suggestive skin lesions, angioid streaks and histologically proven fragmented and calcified elastic fibers on skin biopsy [15]. A control group ($n = 30$) matched for gender and without PAD or cardiovascular events was also recruited for the study.

Medical history, age, body mass index and smoking habits were recorded for all participants. Previous cardiovascular events (stroke and myocardial infarction) and the presence or absence of cardiovascular risk factors were defined according to the following criteria: 1) Hypertension: systolic (SABP) >140 mmHg and diastolic (DABP) >90 mmHg blood pressure and/or use of anti-hypertensive medication, 2) Diabetes: fasting blood glucose ≥ 7.0 mmol/l (≥ 126 mg/dL) and/or use of glucose-lowering medication including insulin, and 3) dyslipidemia: low density (LDL) cholesterol >3.4 mmol/l, high density (HDL) cholesterol lipoproteins <1 mmol/l, triglyceridemia >2 mmol/l and/or use of lipid-lowering medication. Blood samples were collected after overnight fasting for measurement of total cholesterol, LDL, HDL, blood glucose and glycosylated hemoglobin using standard laboratory techniques. Brachial systolic (SABP) and diastolic (DABP) blood pressure were measured in the supine position with an automatic sphygmomanometer (Welch Allyn Inc., Model SPOT, France). Cardiovascular risk stratification of the patients and controls was performed according to the Framingham model [including age, diabetes, smoking, SABP, total and HDL-cholesterol] modified for European populations (F-L score in %) [16], and diabetic patients were excluded from the study. The whole study group was subdivided into three categories according to the Framingham score: high ($>20\%$), intermediate ($10\text{--}20\%$) and low ($<10\%$) risk of cardiovascular events in the next 10 years. (See <http://www.framinghamheartstudy.org/risk-functions/cardiovascular-disease/10-year-risk.php> for further details). All patients gave informed written consent and the study was approved by our local ethics committee (CPP Ouest II – Angers - France) and registered at ClinicalTrials.gov (Identifier #: NCT01446393).

Detection of lower limb peripheral arterial disease

For all participants, the ABI was measured with a bidirectional 8-MHz ultrasound Doppler velocimeter and a pneumatic sphygmomanometer according to standard methods [17]. Ankle systolic pressure was measured in the posterior tibialis and dorsalis pedis arteries of both legs and in the brachial artery of both arms. Determination was performed at least twice for each artery. The ABI was calculated separately for each leg using the highest ankle systolic pressure as the numerator and the highest brachial systolic pressure as the denominator, according to the latest recommendations [13]. The lower of the left or right ABI was considered for determination of PAD. The ABI was considered normal between 0.91 and 1.39 and the presence of PAD was based on an ABI ≤ 0.90 . An ABI >1.40 was suggestive of PAD with non-compressible arterial wall.

Calcium scoring in the lower limb arteries

All participants underwent a non-contrast enhanced 64-row multidetector-computed tomography scan (Brilliance 64, Philips HealthCare, Best, The Netherlands) of the lower limbs, from the iliac crest to the tips of the toes, without injection of contrast medium. All scans were performed according to a standardized protocol including 64×0.625 collimation, at 120 kV with intensity (in mA) adjusted according to the patient's BMI and dose modulation along the Z axis. One millimeter thick slices were reconstructed every 0.7 mm. Calcium scoring was performed

using automated 3D image analysis software (Synapse 3D, Fujifilm Medical Systems, Greenwood, SC, USA) with the investigators blind to the results of the patient's clinical status and ABI. Areas of calcification along the arterial path were identified automatically by the software at 4 pre-specified ranges of density (150, 200, 300 and 400 Hounsfield units, HU). Regions of interest were divided into 3 segments for each leg separately: 1) femoral (including the common and superficial femoral arteries) extending from the iliac crest to the opening of the adductor magnus, 2) popliteal (from the opening of the adductor magna to the origin of the anterior tibial artery) and 3) sub-popliteal (including the anterior and posterior tibialis and fibular arteries from their origin up to the malleolar region). The lengths of all segments were measured on the 3D scans and expressed in mm. Areas of calcification with a cross sectional area ≥ 0.7 mm² and densities ranging between 150 and 400 HU were identified automatically on cross sectional images of the lower extremities. The arterial calcification score (Ca-score) was determined and expressed for each segment of both legs as the Agatston score [18]. The Agatston score of each segment was normalized to its length (HU.mm⁻¹) to allow comparisons between each segment. Finally, an overall Ca-score was determined for each patient by adding together all segmental Ca-scores for both legs. Inter- and intra-observer variability in the determination of the Ca-score was evaluated from a randomly selected list of 10 scans by two different readers.

Statistical analysis

All continuous variables are presented as mean \pm SD. Categorical variables (expressed as %) were compared by Chi2 or exact Fisher's tests. The groups were stratified by age into the following categories: <39 , 40 to 49, 50 to 59, and >60 yrs and divided into 2 groups according to the absence (i.e. a Ca-score = 0) or presence of LLAC (i.e. a Ca-score >0). The patients of the PXE group were also stratified according to ABI (<0.90 or ≥ 0.90). Comparisons between the groups were performed using Kruskal-Wallis tests. Pairwise comparisons between the segmental LLAC scores in each group were performed using Wilcoxon's test for paired data. The confounding role of PXE status, age, gender, LDL cholesterol, smoking, menopausal status and arterial hypertension (independent variables) in LLAC was tested by logistic regression. Association of ABI with LLAC and CV risk factors was tested by logistic regression. All statistical analyses were performed with Stata 12.0 software (StataCorp, Texas, USA) and the level of statistical significance was set at $P \leq 0.05$ for all statistics.

Results

The baseline characteristics of the study population are summarized in Table 1. There were more women (70%) than men among the PXE patients. Forty PXE patients had an ABI <0.90 and none had an ABI >1.40 . Only one woman in the control group had an ABI <0.90 . She was totally asymptomatic and without atherosclerosis on US examination.

Hypertension was more frequent in PXE patients compared to controls. Dyslipidemia was not significantly more prevalent in PXE patients than controls, nor was smoking. The proportion of post-menopausal women was similar between the 2 groups (PXE = 48% vs controls = 36%, $p = 0.444$). Seven PXE patients (10%) had a history of documented coronary artery disease, 6 of whom also had PAD. Eight had a history of ischemic stroke, all associated with PAD. Of the whole cohort, 85% of those with PXE patients and 81% of the controls were at low risk of cardiovascular disease, 12% of the PXE patients and 13% of the controls were at

Table 1. Demographic characteristics and lower leg calcification scores (LLAC) in patients with pseudoxanthoma elasticum (PXE) without (PAD-) or with (PAD+) peripheral arterial disease and controls.

	PXE _{PAD-} (n = 31)		PXE _{PAD+} (n = 40)		overall PXE		Controls (n = 30)		P (chi2)
	6/25	SD	mean	SD	mean	SD	mean	SD	
Gender (m/f)	6/25		15/25		21/50		9/21		0.263
Hypertension (%)	6		40		25		11		0.002
Dyslipidemia (%)	6		47		30		14		0.000
Smoking (%)	26		27		27		18		0.637
Stroke (%)	0		20		11		0		0.001
Myocardial infarction (%)	3		15		10		0		0.048
Age (years)	mean	SD	mean	SD	mean	SD	mean	SD	Ctrl vs PXE _{PAD-}
	43	13	52	13	48	14	43	14	0.007
BMI (kg/m ²)	25	5	26	5	26	5	25	5	0.225
Cardiovascular risk score (%)	1.5	2.1	3.5	3.7	2.6	3.2	2.3	4.2	0.003
Systolic ABP (mmHg)	118	11	125	15	122	14	126	17	0.034
Diastolic ABP (mmHg)	73	10	73	11	73	10	77	14	0.025
Ankle-Brachial Index	1.03	0.08	0.69	0.14	0.84	0.20	1.04	0.10	0.001
Blood glucose (mmol.L ⁻¹)	4.87	0.58	5.19	0.85	5.05	0.76	5.18	0.67	0.089
Total Cholesterol (mmol.L ⁻¹)	4.82	0.96	4.94	0.83	4.89	0.89	5.36	0.96	0.168
LDL (mmol.L ⁻¹)	2.88	0.83	2.93	0.78	2.91	0.80	3.12	0.91	0.675
HBA1C (%)	5.7	0.4	5.7	0.4	5.7	0.4	5.6	0.3	0.498
Arterial calcification (AC) scores									
LLAC (HU)	2998	6145	9355	16137	6658	13188	335	879	<0.0001
Femoral AC (HU.mm ⁻¹)	5.08	12.04	16.93	25.69	11.91	21.70	0.88	2.61	<0.0001
Popliteal AC (HU.mm ⁻¹)	1.63	5.11	5.03	15.01	3.59	11.91	0.10	0.53	<0.0001
Sub-popliteal AC (HU.mm ⁻¹)	3.38	7.00	9.44	22.05	6.87	17.50	0.15	0.40	<0.0001

doi:10.1371/journal.pone.0096003.t001

intermediate risk, while 2% of the PXE and 6% of the controls were at high risk of cardiovascular disease ($p = 0.690$ between groups).

Lower limb arterial calcification

The intra-class correlation coefficient for inter-observer variability for determination of the calcification score was $r = 0.998$ ($p < 0.0001$) and for intra-observer variability it was $r = 0.964$ ($P < 0.001$). In both groups, the Ca-score increased significantly with age and in all segments (figure 1), and LLAC was detected in 95% of the PXE patients with PAD, 68% of the PXE patients without PAD and 32% of the controls. In both groups, the Ca-score was significantly higher in men (PXE: 15103 ± 20521 HU and controls: 531 ± 1029 HU) than in women (PXE: 2717 ± 3951 HU, $p = 0.0004$ and controls = 226 ± 756 HU, $p = 0.013$ vs men). However, whatever the Ca-score, the prevalence of LLAC (i.e. the absence/presence of LLAC) was similar between PXE men (95%) and women (78%, $p = 0.071$) but significantly higher in control men (67%) compared to control women (18%, $p = 0.015$). Although the presence of LLAC was more frequent in the PXE than control women (91% versus 9%), there was no significant difference between the post-menopausal PXE (56%) compared to the controls (75%, $p = 0.628$) when LLAC were present (i.e. a Ca-score > 0). In both groups, the Ca-score was significantly lower in the popliteal segment compared to the femoral and subpopliteal segments. The overall and segmental Ca-scores were significantly higher in PXE patients with PAD compared to PXE patients without PAD and the control group. The presence/absence of LLAC was independently associated with PXE status (OR = 0.06, CI = 0.02–0.20, $p < 0.0001$) and the cardiovascular risk score (OR = 2.49, CI = 1.35–4.57, $p = 0.003$) (table 2) which was mainly due to age (OR = 1.12, CI = 1.05–1.19, $p < 0.0001$). (figure 2).

Relationship between LLAC and ABI

There was a weak but significant inverse relationship between ABI and Ca-score ($r = -0.363$, $p = 0.002$). The ABI was independently associated with the presence of LLAC (OR = 0.11 CI = 0.02–0.55, $p = 0.007$), but not with the cardiovascular risk score (OR = 0.83, CI = 0.67–1.03, $p = 0.091$) (table 3). A low ABI was associated with the presence of calcification in the femoral




Figure 1. Prevalence of lower limb arterial calcification (LLAC) detected in arterial segments in pseudoxanthoma elasticum (PXE) and controls across age. Data are expressed as percentage of the total number of LLAC detected in a given age group. doi:10.1371/journal.pone.0096003.g001




Figure 2. Relationship between Framingham cardiovascular risk score and calcification score in patients with pseudoxanthoma elasticum (PXE) and controls. doi:10.1371/journal.pone.0096003.g002

segment (OR = 0.079, CI = 0.011–0.55, $p = 0.011$) but not in the popliteal (OR = 1.40, CI = 0.32–6.16, $p = 0.658$) or subpopliteal segments (OR = 1.28, CI = 0.21–7.74, $p = 0.791$).

Discussion

Since the pathophysiological role of LLAC in PAD is not fully understood, we decided to focus on PXE, an inherited condition in which AC is associated with a high prevalence of early PAD. We anticipated that this specific condition might disclose important information about the link between LLAC and PAD, independently from atherosclerosis.

Patterns and distribution of arterial calcifications in PXE

Our quantitative analysis based on the CT-scan data confirmed a high prevalence of AC in PXE patients compared to the controls. There was no gender difference in PXE, in contrast to the controls where LLAC was more common in men. As expected, the menopausal status was characterized by a higher prevalence of LLAC [19] but it was not influenced by PXE. The prevalence of AC in our study was much higher than the prevalence of 31% reported in a previous semi-quantitative evaluation of AC based on standard X-ray [7], possibly due to the greater accuracy of CT scans in detecting smaller amounts of calcification. The amount of LLAC increased with age, although there was wide variability. It was barely detected in the controls before forty years of age but was found as early as twenty years of age in PXE patients (figure 1). Compared to other inherited calcifying diseases, the calcification process in PXE is generally considered to be slowly progressive [20], although extensive AC can develop in infancy [21]. The calcification process within the arterial segments of the legs was heterogeneous in both PXE and control groups, with AC predominating in the femoral and subpopliteal arteries (figure 1). In the general population AC is heterogeneously distributed across various vascular beds, predominating in the coronary arteries in men and in the aorta in women [22–24]. This heterogeneity is probably explained by the underlying pathophysiology, with calcification accumulating preferentially within the medial layers of the below-knee arteries in metabolic diseases [25] and within the intima layer of the proximal arteries, such as the femoral artery, where atheroma predominates [24,26]. Since the spatial resolution of the non-contrast enhanced CT-scan was too low to

Table 2. Logistic regressions between lower leg arterial calcification (dependent variable) and selected independent variables.

	Model 1	Model 2
	LLAC	LLAC
PXE status	-2.821 (4.25)**	-3.292 (3.88)**
F-L score	0.911 (2.93)**	
Age		0.115 (3.71)**
Gender		-2.310 (2.53)*
Smoking		0.809 (1.03)
Hypertension		1.161 (0.91)
LDL-C		-0.039 (0.09)
Constant	0.492 (1.25)	-1.527 (0.83)

Absolute value of z statistics in parentheses.

*p<0.05;

**p<0.01.

ABI= Ankle Brachial index, F-L= Framingham-Laurier score, LLAC= lower leg arterial calcification, LDL-C= Low density lipoproteins.

doi:10.1371/journal.pone.0096003.t002

discriminate between the intimal and medial deposition sites of AC, we can only speculate that in PXE, due to young age and the female predominance, AC develops earlier within the medial layers and later within the intima layer, when atheroma becomes obvious with aging. Moreover, the heterogeneous distribution of AC within the arterial segments of the same limb suggested differences in the local balance in anti- and pro-calcifying factors between the limb segments and joints. This could be explained by differences in the embryological origins of the arterial segments [27] and local rheological, hemodynamic and biomechanical strains in cyclic flexural stretching [28]. Interestingly, in contrast to the controls, the calcification process occurred simultaneously in all arterial segments in PXE patients, although the differences

between the segments suggested that the calcification process in PXE is modulated at the local level.

Contribution of arterial calcifications to PAD in PXE

Since PAD and AC are both associated with PXE, we examined the contribution of AC to PAD in this context. In agreement with previous studies [9,29], we observed a high prevalence (44%) of PXE patients with a low ABI at rest. Although ABI was associated with the presence of LLAC, the negative relationship with LLAC was unexpected. In fact, calcium deposition within the arterial wall and fragmentation of elastic fibers [30] were expected to reduce arterial wall compressibility to the pressure exerted by the pneumatic cuffs and increase ABI (i.e. a positive relationship with LLAC) [31,32]. We believe that there are no reports in the

Table 3. Logistic regressions between ankle brachial index (dependent variable) and selected independent variables.

	Model1	Model2
	ABI	ABI
LLAC>0	-2.203 (2.68)**	-1.819 (2.15)*
F-L score		-0.186 (1.69)
Constant	1.609 (2.08)*	1.726 (2.21)*

Absolute value of z statistics in parentheses.

*p<0.05;

**p<0.01,

ABI= Ankle Brachial index, F-L score = Framingham-Laurier cardiovascular risk score, LLAC= lower leg arterial calcification.

doi:10.1371/journal.pone.0096003.t003

literature of ABI >1.40 in other PXE cohorts [7,33] except when associated with diabetes [12]. Reduced compressibility of the arterial wall is generally associated with aging [34] and acquired metabolic diseases such as diabetes [35,36], CKD [37] [38] or Monckeberg's atherosclerotic disease [38,39]. The impact of calcification and elastic fiber fragmentation on arterial stiffness in PXE is unclear, some authors reporting a tendency to increased arterial stiffness [33], and others reduced stiffness [30,40] or increased wall compressibility [41]. Our findings together suggest that AC in PXE is not accompanied by increased stiffness of the arterial wall. This conclusion needs to be viewed with caution since an association between AC and PAD has not been clearly established in other calcifying diseases [13,31]. In diabetics with incompressible arteries (i.e. ABI>1.40), a poorer prognosis has been reported to be linked to obstructive arterial disease compared to those with medial calcification alone [42]. The low ABI in our study was preferentially associated with calcification of the femoral segment, suggesting that the drop in peripheral pressure is linked to the development of an arterial obstruction in the proximal arterial segments rather than calcification in the distal arteries. This finding is in accordance with the fact that ischemia requiring surgery often occurs in PXE patients suffering from proximal lesions [43,44]. Although the pressure drop below a proximal stenosis can be the most probable explanation to the low ABI, changes in arterial stiffness and compliance, and arterial wave reflection should be considered, but were not measured in the present study. We described recently the vascular phenotype of a murin model of PXE (Kauffenstein et al. ATVB in press). Noteworthy, these animals displayed scattered arterial calcium deposition with a lower elasticity and increased myogenic tone. Such changes may be a consequence of metabolic changes associated to the ABCC6 deficiency and could also contribute to our findings.

Contribution of CV risk factors to AC and PAD in PXE

Our findings showed wide variations in the amount of AC, which increased with age and suggested that confounding factors contribute to the severity of the calcification process in PXE [45]. The common vascular risk factors should be considered first as potential contributors to the severity of both AC and PAD in PXE. A large majority of the PXE patients studied were at low risk for CV events according to the Framingham equation, although those with PXE and PAD were at higher risk of CV events since they were mostly older men. In accordance with recent findings, aging

was the most prominent CV risk factor related to the severity of the calcification process [46]. On the other hand, the fact that ABI was not associated with CV risk factors suggests that PAD in PXE is not linked to common risk factors, but probably to a unique remodeling process.

Study limitations

The cross-sectional design of this study did not allow us to determine the pattern progression of the calcification process and/or its potential impact on the overall cardiovascular morbidity-mortality of these patients. In contrast to the coronary vascular bed, where calcium scoring has been extensively studied using CT-scans, scoring of the calcification of the lower limb vessels has been less frequently evaluated [14] and a risk threshold remains to be determined. Despite this, our findings are consistent with the fact that AC is an early, slow process, taking several decades to develop, with wide inter-individual variability. In the absence of a validated risk threshold value for limb AC, the diagnosis and prognostic value of the calcification score remains to be determined prospectively in PXE.

Conclusions

The present findings provide new information on the impact of calcification on arterial wall stiffness in PXE. Although calcification is a major phenotypic trait associated with PXE, it is likely that PAD results from complex remodeling occurring in proximal segments. Furthermore, both LLAC and PAD are differentially affected by local and systemic cardiovascular risk factors. Further studies are needed to determine the unique mechanisms leading to arterial occlusion in PXE.

Acknowledgments

We wish to thank the medical staff, patients and controls who participated in this study, the PXE-France Patients' Association. We also thank Mrs C Cochard for her technical help in CT-scan analysis and Mrs S Marechal-Girault and N Navasiolava for their continuing technical assistance.

Author Contributions

Conceived and designed the experiments: GL LM GK. Performed the experiments: GL LM SW. Analyzed the data: GL LM JFH. Contributed reagents/materials/analysis tools: DH JFH SW. Wrote the paper: GL GK PA LM. Drafted and revised the manuscript: DH OLS.

References

- Wittean JC, Kok FJ, van Saase JL, Valkenburg HA (1986) Aortic calcification as a predictor of cardiovascular mortality. *Lancet* 2: 1120–1122.
- Levitzyk YS, Cupples LA, Murabito JM, Kannel WB, Kiel DP, et al. (2008) Prediction of intermittent claudication, ischemic stroke, and other cardiovascular disease by detection of abdominal aortic calcific deposits by plain lumbar radiographs. *Am J Cardiol* 101: 326–331.
- Persy V, D'Haese P (2009) Vascular calcification and bone disease: the calcification paradox. *Trends Mol Med* 15: 405–416.
- Leftheriotis G, Omarjee L, Le Saux O, Henrion D, Abraham P, et al. (2013) The vascular phenotype in Pseudoxanthoma elasticum and related disorders: contribution of a genetic disease to the understanding of vascular calcification. *Front Genet* 4: 4.
- Li Q, Jiang Q, Pfendner E, Varadi A, Uitto J (2009) Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms. *Exp Dermatol* 18: 1–11.
- Le Saux O, Urban Z, Tschuch C, Csizsar K, Bacchelli B, et al. (2000) Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. *Nat Genet* 25: 223–227.
- Neldner KH (1988) Pseudoxanthoma elasticum. *Clin Dermatol* 6: 1–159.
- Chassaing N, Martin L, Calvas P, Le Bert M, Hovnanian A (2005) Pseudoxanthoma elasticum: a clinical, pathophysiological and genetic update including 11 novel ABCC6 mutations. *J Med Genet* 42: 881–892.
- Vanakker OM, Leroy BP, Coucke P, Bercovitch LG, Uitto J, et al. (2008) Novel clinico-molecular insights in pseudoxanthoma elasticum provide an efficient molecular screening method and a comprehensive diagnostic flowchart. *Hum Mutat* 29: 205.
- von Beckerath O, Gaa J, von Mohrenfels CW, von Beckerath N (2008) Images in cardiovascular medicine. Intermittent claudication in a 28-year-old man with pseudoxanthoma elasticum. *Circulation* 118: 102–104.
- Donas KP, Schulte S, Horsch S (2007) Balloon angioplasty in the treatment of vascular lesions in pseudoxanthoma elasticum. *J Vasc Interv Radiol* 18: 457–459.
- Leftheriotis G, Abraham P, Le Corre Y, Le Saux O, Henrion D, et al. (2011) Relationship between ankle brachial index and arterial remodeling in pseudoxanthoma elasticum. *J Vasc Surg* 54: 1390–1394.
- Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, et al. (2012) Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. *Circulation* 126: 2890–2909.
- Ohtake T, Oka M, Ikee R, Mochida Y, Ishioka K, et al. (2011) Impact of lower limbs' arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. *Journal of vascular surgery* 53: 676–683.
- Lebwohl M, Neldner K, Pope FM, De Paepe A, Christiano AM, et al. (1994) Classification of pseudoxanthoma elasticum: report of a consensus conference. *J Am Acad Dermatol* 30: 103–107.

16. Laurier D, Nguyen PC, Cazelles B, Segond P (1994) Estimation of CHD risk in a French working population using a modified Framingham model. The PCV-METRA Group. *J Clin Epidemiol* 47: 1353–1364.
17. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, et al. (1993) Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Health Study (CHS) Collaborative Research Group. *Circulation* 88: 837–845.
18. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, et al. (1990) Quantification of coronary artery calcium using ultrafast computed tomography. *J Am Coll Cardiol* 15: 827–832.
19. Kuller LH, Matthews KA, Sutton-Tyrrell K, Edmundowicz D, Bunker CH (1999) Coronary and aortic calcification among women 8 years after menopause and their premenopausal risk factors: the healthy women study. *Arterioscler Thromb Vasc Biol* 19: 2189–2198.
20. Nitschke Y, Baujat Gv, Botschen U, Wittkamp T, du Moulin M, et al. (2012) Generalized Arterial Calcification of Infancy and Pseudoxanthoma Elasticum Can Be Caused by Mutations in Either ENPP1 or ABCG6. *The American Journal of Human Genetics*.
21. Le Boulanger G, Labreze C, Croue A, Schurgers IJ, Chassaing N, et al. (2010) An unusual severe vascular case of pseudoxanthoma elasticum presenting as generalized arterial calcification of infancy. *Am J Med Genet A* 152A: 118–123.
22. DeBakey ME, Glaeser DH (2000) Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. *Am J Cardiol* 85: 1045–1053.
23. Nasir K, Roguin A, Sarwar A, Rumberger JA, Blumenthal RS (2007) Gender differences in coronary arteries and thoracic aorta calcification. *Arterioscler Thromb Vasc Biol* 27: 1220–1222.
24. Allison MA, Criqui MH, Wright CM (2004) Patterns and risk factors for systemic calcified atherosclerosis. *Arterioscler Thromb Vasc Biol* 24: 331–336.
25. Raptis AE, Markakis KP, Mazioti MC, Raptis SA, Dimitriadis GD (2011) What the radiologist needs to know about the diabetic patient. *Insights Imaging* 2: 193–203.
26. Herisson F, Heymann M-F, Chetiveaux M, Charrier C, Battaglia S, et al. (2011) Carotid and femoral atherosclerotic plaques show different morphology. *Atherosclerosis* 216: 348–354.
27. Mauro MA, Jaques PF, Moore M (1988) The popliteal artery and its branches: embryologic basis of normal and variant anatomy. *AJR Am J Roentgenol* 150: 435–437.
28. Xu HG, Li ZR, Wang H, Liu P, Xiang SN, et al. (2013) Intermittent Cyclic Mechanical Tension-induced Down-regulation of Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Gene Expression is Mainly Dependent on TGF-beta1 in End-plate Chondrocytes. *Orthop Surg* 5: 40–45.
29. Brampton C, Yamaguchi Y, Vanakker O, Van Laer L, Chen LH, et al. (2011) Vitamin K does not prevent soft tissue mineralization in a mouse model of pseudoxanthoma elasticum. *Cell Cycle* 10: 1810–1820.
30. Kornet L, Bergen AA, Hoeks AP, Cleutjens JP, Oostra RJ, et al. (2004) In patients with pseudoxanthoma elasticum a thicker and more elastic carotid artery is associated with elastin fragmentation and proteoglycans accumulation. *Ultrasound Med Biol* 30: 1041–1048.
31. Aerden D, Massaad D, von Kemp K, van Tussenbroek F, Debing E, et al. (2011) The Ankle-Brachial Index and the Diabetic Foot: A Troublesome Marriage. *Annals of Vascular Surgery* 25: 770–777.
32. Rabkin SW, Chan SH, Sweeney C (2012) Ankle-Brachial Index as an Indicator of Arterial Stiffness in Patients Without Peripheral Artery Disease. *Angiology* 63: 150–154.
33. Campens L, Vanakker OM, Trachet B, Segers P, Leroy BP, et al. (2013) Characterization of cardiovascular involvement in pseudoxanthoma elasticum families. *Arterioscler Thromb Vasc Biol* 33: 2646–2652.
34. Allison MA, Hiatt WR, Hirsch AT, Coll JR, Criqui MH (2008) A high ankle-brachial index is associated with increased cardiovascular disease morbidity and lower quality of life. *J Am Coll Cardiol* 51: 1292–1298.
35. David Smith C, Gavin Bilmen J, Iqbal S, Robey S, Pereira M (2008) Medial artery calcification as an indicator of diabetic peripheral vascular disease. *Foot Ankle Int* 29: 185–190.
36. Aboyans V, Ho E, Denenberg JO, Ho LA, Natarajan L, et al. (2008) The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects. *J Vasc Surg* 48: 1197–1203.
37. Ix JH, Katz R, De Boer IH, Kestenbaum BR, Allison MA, et al. (2009) Association of chronic kidney disease with the spectrum of ankle brachial index the CHS (Cardiovascular Health Study). *J Am Coll Cardiol* 54: 1176–1184.
38. Amann K (2008) Media calcification and intima calcification are distinct entities in chronic kidney disease. *Clin J Am Soc Nephrol* 3: 1599–1605.
39. Shanahan CM, Cary NRB, Salisbury JR, Proudfoot D, Weissberg PL, et al. (1999) Medial Localization of Mineralization-Regulating Proteins in Association With Monckeberg's Sclerosis: Evidence for Smooth Muscle Cell-Mediated Vascular Calcification. *Circulation* 100: 2168–2176.
40. Germain DP, Boutouyrie P, Laloux B, Laurent S (2003) Arterial remodeling and stiffness in patients with pseudoxanthoma elasticum. *Arterioscler Thromb Vasc Biol* 23: 836–841.
41. Boutouyrie P, Germain DP, Tropeano AI, Laloux B, Carenzi F, et al. (2001) Compressibility of the carotid artery in patients with pseudoxanthoma elasticum. *Hypertension* 38: 1181–1184.
42. Aboyans V, Lacroix P, Tran MH, Salamagne C, Galinat S, et al. (2011) The prognosis of diabetic patients with high ankle-brachial index depends on the coexistence of occlusive peripheral artery disease. *J Vasc Surg* 53: 984–991.
43. Siskos D, Giannakakis S, Makris S, Pirgakis K, Psyllas A, et al. (2012) Case Report of a Patient With Iliac Occlusive Disease Due to Pseudoxanthoma Elasticum and Review of the Bibliography. *Annals of Vascular Surgery* 26: 278.e211–278.e214.
44. Zuily Sp, Angioi K, Fauret A-L, Golmard L, Saadi LI, et al. (2012) Severe and Diffuse Arterial Lesions in a Patient With Pseudoxanthoma Elasticum. *Journal of the American College of Cardiology* 59: 1991.
45. Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, et al. (2003) Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. *Surv Ophthalmol* 48: 424–438.
46. Morbelli S, Fiz F, Piccardo A, Picori L, Massollo M, et al. (2013) Divergent determinants of F-NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. *Int J Cardiovasc Imaging*.